- Home
- OM vs XGN Comparison
OM vs XGN Comparison
Compare OM & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OM | XGN |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.4M | 73.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OM | XGN |
|---|---|---|
| Price | $4.78 | $3.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $13.33 | $8.86 |
| AVG Volume (30 Days) | 106.9K | ★ 198.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,476,000.00 | N/A |
| Revenue This Year | $9.29 | $8.12 |
| Revenue Next Year | $10.99 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.09 | N/A |
| 52 Week Low | $3.00 | $2.59 |
| 52 Week High | $21.98 | $12.23 |
Technical Indicators
Market Signals| Indicator | OM | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 67.67 | 56.07 |
| Support Level | $3.08 | $2.61 |
| Resistance Level | $4.90 | $3.29 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 92.36 | 74.60 |
Price Performance
Historical ComparisonAbout OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.